By serological means it has been shown that E. coli B contains an antigen closely related to the protein-lipocarbohydrate complex of Phase II Sh. sonnei. Lysis of E. coli B by three of the T viruses, T(3), T(4), and T(7), can be inhibited by the Phase II dysentery antigen. It has been suggested that the receptor of E. coli B with which these viruses combine is this newly described antigenic component. Two variants of the virus T(3) have also been described, in stocks which have been treated with the Phase II antigen. One of these variants infects both Phase II Sh. sonnei and E. coli B, and the other infects only the latter microorganism; neither of the two variants is inhibited by concentrations of the Phase II antigen of 1 mg. per cc. The distinctive properties of the variants are not hereditary.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2135995 | PMC |
| http://dx.doi.org/10.1084/jem.92.6.527 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: We report data from stage 1 of an ongoing 2-staged, phase 1/2 randomized clinical trial with a 4-component generalized modules for membrane antigens-based vaccine against Shigella sonnei and Shigella flexneri 1b, 2a, and 3a (altSonflex1-2-3; GSK).
Methods: Europeans aged 18-50 years (N = 102) were randomized (2:1) to receive 2 injections of altSonflex1-2-3 or placebo at 3- or 6-month interval. Safety and immunogenicity were assessed at prespecified time points.
Shigella spp. are a leading bacterial cause of diarrhea. No widely licensed vaccines are available and there is no generally accepted correlate of protection.
View Article and Find Full Text PDFB memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3.
PLoS One
January 2024
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
B memory (BM) cell responses were evaluated using peripheral blood mononuclear cells that were collected and cryopreserved during a Phase 1 trial of two live Shigella sonnei vaccine candidates WRSs2 and WRSs3. An ELISpot assay was used to measure IgG+ and IgA+ BM cell responses against S. sonnei LPS, IVP and IpaB antigens.
View Article and Find Full Text PDFArticle Synopsis
- - Shigellosis is a common cause of diarrhea, especially in young children in low- and middle-income countries, with rising cases linked to antibiotic resistance, and there are currently no licensed vaccines.
- - Researchers are testing a new 4-component GMMA vaccine candidate in a clinical trial to see if it can provide broader protection against prevalent Shigella serotypes, comparing its effectiveness to traditional glycoconjugate vaccines in animal models.
- - Results show that the GMMA vaccine induces stronger antibody responses and bactericidal activity than traditional options, suggesting it may be more effective, but further studies are needed to see if these findings hold true in humans.
Trends in antimicrobial resistance of species in Peru, 2011-2020.
JAC Antimicrob Resist
October 2023
Laboratorio de Referencia Nacional de Bacteriología Clínica, Instituto Nacional de Salud, Lima, Perú.
Article Synopsis
- The study analyzed 1,668 strains of enteric pathogens collected in Peru over the past 10 years to assess antimicrobial resistance rates and how they changed over time and location.
- The most commonly identified species were resistant to several antibiotics, with particularly high resistance rates observed for trimethoprim/sulfamethoxazole (91.0%) and tetracycline (88.4%), and a concerning increase in resistance to fluoroquinolones from 2017 to 2020.
- The findings underline the dominance of a specific species resistant to common antibiotics, raising alarms about increasing resistance and the implications for treatment of infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!